Dashboard
Manage Tickers

RIGL RIGEL PHARMACEUTICALS INC

Nasdaq rigel.com


$ 38.04 $ 0.00 (0 %)    

Thursday, 06-Nov-2025 04:09:43 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 623.50 $ 0.00 (0 %)
DIA $ 473.03 $ 0.00 (0 %)
SPY $ 677.87 $ 0.00 (0 %)
TLT $ 89.10 $ 0.00 (0 %)
GLD $ 368.91 $ 0.00 (0 %)
$ 37.85
$ 34.87
$ 37.86 x 305
$ 39.00 x 210
-- - --
$ 14.47 - $ 43.72
2,326,568
na
687.03M
$ 1.04
$ 6.06
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-04-2025 09-30-2025 10-Q
2 08-05-2025 06-30-2025 10-Q
3 05-06-2025 03-31-2025 10-Q
4 03-04-2025 12-31-2024 10-K
5 11-07-2024 09-30-2024 10-Q
6 08-06-2024 06-30-2024 10-Q
7 05-07-2024 03-31-2024 10-Q
8 03-05-2024 12-31-2023 10-K
9 11-07-2023 09-30-2023 10-Q
10 08-01-2023 06-30-2023 10-Q
11 05-02-2023 03-31-2023 10-Q
12 03-07-2023 12-31-2022 10-K
13 11-03-2022 09-30-2022 10-Q
14 08-02-2022 06-30-2022 10-Q
15 05-03-2022 03-31-2022 10-Q
16 03-01-2022 12-31-2021 10-K
17 11-02-2021 09-30-2021 10-Q
18 08-03-2021 06-30-2021 10-Q
19 05-05-2021 03-31-2021 10-Q
20 03-02-2021 12-31-2020 10-K
21 11-05-2020 09-30-2020 10-Q
22 08-04-2020 06-30-2020 10-Q
23 05-05-2020 03-31-2020 10-Q
24 02-27-2020 12-31-2019 10-K
25 11-05-2019 09-30-2019 10-Q
26 08-06-2019 06-30-2019 10-Q
27 05-07-2019 03-31-2019 10-Q
28 02-28-2019 12-31-2018 10-K
29 11-06-2018 09-30-2018 10-Q
30 08-08-2018 06-30-2018 10-Q
31 05-01-2018 03-31-2018 10-Q
32 03-06-2018 12-31-2017 10-K
33 11-07-2017 09-30-2017 10-Q
34 08-01-2017 06-30-2017 10-Q
35 05-02-2017 03-31-2017 10-Q
36 03-07-2017 12-31-2016 10-K
37 11-01-2016 09-30-2016 10-Q
38 08-02-2016 06-30-2016 10-Q
39 05-03-2016 03-31-2016 10-Q
40 03-08-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

jefferies-upgrades-rigel-pharmaceuticals-to-buy-raises-price-target-to-42
Jefferies Upgrades Rigel Pharmaceuticals t...
11/05/2025 22:10:54

Jefferies analyst Eun Yang upgrades Rigel Pharmaceuticals (NASDAQ:RIGL) from Hold to Buy and raises the price target from $2...

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
11/05/2025 17:05:53

johnson-controls-babcock--wilcox-lemonade-lumentum-teva-pharmaceutical-and-other-big-stocks-moving-higher-on-wednesday
Johnson Controls, Babcock & Wilcox, Lemona...
11/05/2025 16:56:53

cantor-fitzgerald-maintains-neutral-on-rigel-pharmaceuticals-raises-price-target-to-38
Cantor Fitzgerald Maintains Neutral on Rig...
11/05/2025 15:48:14

Cantor Fitzgerald analyst Kristen Kluska maintains Rigel Pharmaceuticals (NASDAQ:RIGL) with a Neutral and raises the price t...

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
11/05/2025 12:05:48

why-teradata-shares-are-trading-higher-by-around-15-here-are-20-stocks-moving-premarket
Why Teradata Shares Are Trading Higher By ...
11/05/2025 10:09:59

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
11/04/2025 21:06:29

rigel-pharmaceuticals-raises-fy2025-sales-guidance-from-210000m-220000m-to-285000m-290000m-vs-281095m-est
Rigel Pharmaceuticals Raises FY2025 Sales ...
11/04/2025 21:04:51

Rigel Pharmaceuticals (NASDAQ:RIGL) raises FY2025 sales outlook from $210.000 million-$220.000 million to $285.000 million-$290...

rigel-pharmaceuticals-q3-eps-146-beats-084-estimate-sales-69462m-beat-61880m-estimate
Rigel Pharmaceuticals Q3 EPS $1.46 Beats $...
11/04/2025 21:03:46

Rigel Pharmaceuticals (NASDAQ:RIGL) reported quarterly earnings of $1.46 per share which beat the analyst consensus estimate of...

earnings-scheduled-for-november-4-2025
Earnings Scheduled For November 4, 2025
11/04/2025 11:12:08

a-look-ahead-rigel-pharmaceuticalss-earnings-forecast
A Look Ahead: Rigel Pharmaceuticals's Earn...
11/03/2025 19:03:11

rigel-pharma-announces-first-patient-enrolled-in-dose-expansion-phase-of-ongoing-phase-1b-study-of-r2891-in-patients-with-rr-lower-risk-mds-earlier-today
Rigel Pharma Announces First Patient Enrol...
10/08/2025 14:29:09

Dose expansion phase will determine the recommended Phase 2 dose of R289 for patients with transfusion dependent R/R lower-risk...

hc-wainwright--co-reiterates-buy-on-rigel-pharmaceuticals-maintains-57-price-target
HC Wainwright & Co. Reiterates Buy on Rige...
10/08/2025 14:19:07

HC Wainwright & Co. analyst Joseph Pantginis reiterates Rigel Pharmaceuticals (NASDAQ:RIGL) with a Buy and maintains $57...

freeport-mcmoran-harmony-biosciences-cohu-and-other-big-stocks-moving-lower-on-wednesday
Freeport-McMoRan, Harmony Biosciences, Coh...
09/24/2025 18:18:13

cantor-fitzgerald-maintains-neutral-on-rigel-pharmaceuticals-raises-price-target-to-32
Cantor Fitzgerald Maintains Neutral on Rig...
08/06/2025 14:12:29

Cantor Fitzgerald analyst Kristen Kluska maintains Rigel Pharmaceuticals (NASDAQ:RIGL) with a Neutral and raises the price t...

rigel-pharmaceuticals-q2-eps-328-beats-019-estimate-sales-101685m-beat-48142m-estimate
Rigel Pharmaceuticals Q2 EPS $3.28 Beats $...
08/05/2025 20:11:24

Rigel Pharmaceuticals (NASDAQ:RIGL) reported quarterly earnings of $3.28 per share which beat the analyst consensus estimate of...

rigel-pharmaceuticals-raises-fy2025-sales-guidance-from-200000m-210000m-to-210000m-220000m-vs-201095m-est
Rigel Pharmaceuticals Raises FY2025 Sales ...
08/05/2025 20:05:44

Rigel Pharmaceuticals (NASDAQ:RIGL) raises FY2025 sales outlook from $200.000 million-$210.000 million to $210.000 million-$220...

Core News & Articles
Earnings Scheduled For August 5, 2025
08/05/2025 08:32:54

what-to-expect-from-rigel-pharmaceuticalss-earnings
What to Expect from Rigel Pharmaceuticals'...
08/04/2025 20:06:18

rigel-pharmaceuticals-to-present-final-gavreto-phase-12-arrow-study-data-in-ret-fusion-positive-nsclc-and-solid-tumors-along-with-supportive-rezlidhia-data-for-midh1-rr-aml-at-asco-and-eha-2025-conferences
Rigel Pharmaceuticals To Present Final GAV...
05/22/2025 21:36:10

Final data from the GAVRETO® (pralsetinib) Phase 1/2 ARROW study in RET fusion-positive NSCLC and other solid tumors  Supportiv...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION